AP848A - 6-Phenylpyridyl-2-amine derivatives useful as NOS inhibitors. - Google Patents

6-Phenylpyridyl-2-amine derivatives useful as NOS inhibitors. Download PDF

Info

Publication number
AP848A
AP848A APAP/P/1997/001156A AP9701156A AP848A AP 848 A AP848 A AP 848A AP 9701156 A AP9701156 A AP 9701156A AP 848 A AP848 A AP 848A
Authority
AP
ARIPO
Prior art keywords
nmr
disease
cdci
mmol
parent
Prior art date
Application number
APAP/P/1997/001156A
Other languages
English (en)
Other versions
AP9701156A0 (en
Inventor
Iii John Adams Lowe
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of AP9701156A0 publication Critical patent/AP9701156A0/xx
Application granted granted Critical
Publication of AP848A publication Critical patent/AP848A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/73—Unsubstituted amino or imino radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Psychiatry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Psychology (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Immunology (AREA)
  • Addiction (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
APAP/P/1997/001156A 1996-12-06 1997-12-04 6-Phenylpyridyl-2-amine derivatives useful as NOS inhibitors. AP848A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US3279396P 1996-12-06 1996-12-06
PCT/IB1997/001446 WO1998024766A1 (fr) 1996-12-06 1997-11-17 Derives de 6-phenylpyridyl-2-amine utilises comme inhibiteurs de nos

Publications (2)

Publication Number Publication Date
AP9701156A0 AP9701156A0 (en) 1998-01-31
AP848A true AP848A (en) 2000-06-09

Family

ID=21866837

Family Applications (1)

Application Number Title Priority Date Filing Date
APAP/P/1997/001156A AP848A (en) 1996-12-06 1997-12-04 6-Phenylpyridyl-2-amine derivatives useful as NOS inhibitors.

Country Status (42)

Country Link
US (3) US6235750B1 (fr)
EP (1) EP0946512B1 (fr)
JP (2) JP3604399B2 (fr)
KR (1) KR100360633B1 (fr)
CN (1) CN1117077C (fr)
AP (1) AP848A (fr)
AR (1) AR010331A1 (fr)
AT (1) ATE251612T1 (fr)
AU (2) AU4791797A (fr)
BG (1) BG103540A (fr)
BR (1) BR9714381A (fr)
CA (1) CA2273479C (fr)
CZ (1) CZ293863B6 (fr)
DE (1) DE69725465T2 (fr)
DK (1) DK0946512T3 (fr)
DZ (1) DZ2361A1 (fr)
EA (1) EA002907B1 (fr)
ES (1) ES2206691T3 (fr)
HN (2) HN1997000027A (fr)
HR (1) HRP970664A2 (fr)
HU (1) HUP0001848A3 (fr)
ID (1) ID19056A (fr)
IL (1) IL130111A0 (fr)
IS (1) IS5053A (fr)
MA (1) MA26453A1 (fr)
NO (1) NO313517B1 (fr)
NZ (1) NZ335733A (fr)
OA (1) OA11123A (fr)
PA (1) PA8442201A1 (fr)
PE (1) PE46499A1 (fr)
PL (1) PL333918A1 (fr)
PT (1) PT946512E (fr)
SI (1) SI0946512T1 (fr)
SK (1) SK70899A3 (fr)
TN (1) TNSN97198A1 (fr)
TR (1) TR199901259T2 (fr)
TW (1) TW491840B (fr)
UA (1) UA59379C2 (fr)
UY (1) UY24799A1 (fr)
WO (1) WO1998024766A1 (fr)
YU (1) YU25399A (fr)
ZA (1) ZA9710906B (fr)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ326874A (en) * 1996-03-29 2000-01-28 Pfizer 6-phenylpyridyl-2-amine derivatives
US20010049379A1 (en) 1997-08-27 2001-12-06 Lowe John Adams 2-aminopyridines containing fused ring substituents
HN1998000118A (es) * 1997-08-27 1999-02-09 Pfizer Prod Inc 2 - aminopiridinas que contienen sustituyentes de anillos condensados.
HN1998000125A (es) 1997-08-28 1999-02-09 Pfizer Prod Inc 2-aminopiridinas con sustituyentes alcoxi ramificados
CN1303379A (zh) 1998-06-03 2001-07-11 辉瑞产品公司 作为氧化氮合酶抑制剂的含稠环取代基的2－氨基吡啶
FR2791674A1 (fr) * 1999-04-02 2000-10-06 Sod Conseils Rech Applic Nouveaux derives de 2-aminopyridines, leur utilisation en tant que medicaments et compositions pharmaceutiques les contenant
FR2780971B1 (fr) * 1998-07-08 2001-09-28 Sod Conseils Rech Applic Nouveaux derives de 2-aminopyridines, leur application en tant que medicaments et compositions pharmaceutiques les contenant
AR019190A1 (es) * 1998-07-08 2001-12-26 Sod Conseils Rech Applic Derivados de 2-aminopiridinas, productos intermedios para su preparacion, medicamentos y composiciones farmaceuticas que los contienen y su uso para preparar medicamentos
HUP0103113A3 (en) * 1998-08-11 2002-02-28 Pfizer Prod Inc New pharmaceutical compositions uses for nos inhibitors
US7115557B2 (en) 1998-09-25 2006-10-03 Sciaticon Ab Use of certain drugs for treating nerve root injury
SE9803710L (sv) 1998-09-25 2000-03-26 A & Science Invest Ab Användning av vissa substanser för behandling av nervrotsskador
CA2364719C (fr) 1999-02-25 2006-07-04 Pfizer Products Inc. 2-aminopyridines contenant des substituants a cycles condenses
BR0012697A (pt) * 1999-07-23 2002-04-09 Shionogi & Co Inibidores da diferenciação de th2
FR2804429B1 (fr) * 2000-01-31 2003-05-09 Adir Nouveaux derives de 4-sulfonamides piperidine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
AU2002303264A1 (en) * 2001-04-09 2002-10-21 Bristol-Myers Squibb Company Fused heterocyclic inhibitors of factor xa
US20030045449A1 (en) * 2001-08-15 2003-03-06 Pfizer, Inc. Pharmaceutical combinations for the treatment of neurodegenerative diseases
BRPI0409307A (pt) * 2003-04-14 2006-04-25 Pfizer Prod Inc derivados de 3-azabiciclo[3.2.1]octano
CN1295216C (zh) * 2003-07-04 2007-01-17 中国人民解放军军事医学科学院毒物药物研究所 吲哚酮类衍生物及其用于制备抗肿瘤药物的用途
US20080070952A1 (en) * 2005-02-21 2008-03-20 Proximagen Ltd., Inhibition or Treatment of Dyskinesia
WO2006105795A1 (fr) * 2005-04-08 2006-10-12 Leo Pharma A/S Nouveaux dérivés d'indolinone
US8633175B2 (en) 2006-08-09 2014-01-21 Glaxosmithkline Llc Compounds as antagonists or inverse agonists at opioid receptors
JO2972B1 (en) 2007-06-08 2016-03-15 جانسين فارماسوتيكا ان. في Piperidine / piperazine derivatives
JP5443342B2 (ja) 2007-06-08 2014-03-19 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ ピペリジン／ピペラジン誘導体
EP2152270B1 (fr) 2007-06-08 2015-03-04 Janssen Pharmaceutica, N.V. Dérivés de piperidine/piperazine
ES2483898T3 (es) 2007-06-08 2014-08-08 Janssen Pharmaceutica, N.V. Derivados de piperidina/piperazina
PE20100083A1 (es) 2008-06-05 2010-02-17 Janssen Pharmaceutica Nv Combinaciones de drogas que comprenden un inhibidor de dgat y un agonista de ppar
UA105182C2 (ru) 2008-07-03 2014-04-25 Ньюрексон, Інк. Бензоксазины, бензотиазины и родственные соединения, которые имеют ингибирующую nos активность
JP5642661B2 (ja) * 2009-03-05 2014-12-17 塩野義製薬株式会社 Ｎｐｙｙ５受容体拮抗作用を有するピペリジンおよびピロリジン誘導体
US11013844B2 (en) * 2014-11-20 2021-05-25 City Of Hope Treatment device for plasma virus inactivation
US10213435B2 (en) * 2016-08-12 2019-02-26 Athenex, Inc. Biaryl compositions and methods for modulating a kinase cascade
RU2764243C2 (ru) 2017-09-22 2022-01-14 ДЖУБИЛАНТ ЭПИПЭД ЭлЭлСи Гетероциклические соединения в качестве ингибиторов PAD
CN111225915B (zh) 2017-10-18 2023-03-07 朱比兰特埃皮帕德有限公司 作为pad抑制剂的咪唑并吡啶化合物
US11629135B2 (en) 2017-11-06 2023-04-18 Jubilant Prodell Llc Pyrimidine derivatives as inhibitors of PD1/PD-L1 activation
RS65576B1 (sr) 2017-11-24 2024-06-28 Jubilant Episcribe Llc Heterociklična jedinjenja kao inhibitori prmt5
CN112105610B (zh) 2018-03-13 2024-01-26 朱比连特普罗德尔有限责任公司 作为pd1/pd-l1相互作用/活化的抑制剂的双环化合物
CA3142890A1 (fr) * 2019-06-14 2020-12-17 Srx Cardio, Llc Composes pour la modulation de la proproteine convertase subtilisine/kexine de type 9 (pcsk9)
US12115154B2 (en) * 2020-12-16 2024-10-15 Srx Cardio, Llc Compounds for the modulation of proprotein convertase subtilisin/kexin type 9 (PCSK9)

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992014780A1 (fr) 1991-02-19 1992-09-03 Akzo N.V. Copolymers stabilises de monoxyde de carbone et d'olefine
EP0674627A1 (fr) * 1992-12-18 1995-10-04 The Wellcome Foundation Limited Derives de pyrimidine, de pyridine, de pteridinone et d'indazole utilises comme inhibiteurs enzymatiques
US5621004A (en) 1994-06-03 1997-04-15 Robert W. Dunn Method for treating emesis
AU4515696A (en) * 1994-12-12 1996-07-03 Merck & Co., Inc. Substituted 2-aminopyridines as inhibitors of nitric oxide synthase
NZ326874A (en) * 1996-03-29 2000-01-28 Pfizer 6-phenylpyridyl-2-amine derivatives
US6093743A (en) 1998-06-23 2000-07-25 Medinox Inc. Therapeutic methods employing disulfide derivatives of dithiocarbamates and compositions useful therefor

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
NONE *

Also Published As

Publication number Publication date
CA2273479C (fr) 2006-02-07
TNSN97198A1 (fr) 2005-03-15
ES2206691T3 (es) 2004-05-16
JP3604399B2 (ja) 2004-12-22
BR9714381A (pt) 2000-05-02
SI0946512T1 (en) 2004-04-30
AU766080B2 (en) 2003-10-09
DE69725465T2 (de) 2004-05-06
UA59379C2 (uk) 2003-09-15
EP0946512A1 (fr) 1999-10-06
YU25399A (sh) 2001-07-10
PL333918A1 (en) 2000-01-31
CA2273479A1 (fr) 1998-06-11
HN1997000149A (es) 1997-12-26
AP9701156A0 (en) 1998-01-31
JP2005170924A (ja) 2005-06-30
UY24799A1 (es) 2001-08-27
ATE251612T1 (de) 2003-10-15
CZ293863B6 (cs) 2004-08-18
US20020103227A1 (en) 2002-08-01
HUP0001848A2 (hu) 2001-04-28
NO992725D0 (no) 1999-06-04
AR010331A1 (es) 2000-06-07
JP2000505814A (ja) 2000-05-16
US6235750B1 (en) 2001-05-22
EA002907B1 (ru) 2002-10-31
TW491840B (en) 2002-06-21
BG103540A (bg) 2000-12-29
EA199900448A1 (ru) 2000-02-28
ID19056A (id) 1998-06-11
NO992725L (no) 1999-06-04
CN1117077C (zh) 2003-08-06
CZ201799A3 (cs) 2000-07-12
PE46499A1 (es) 1999-05-12
EP0946512B1 (fr) 2003-10-08
IS5053A (is) 1999-05-18
PA8442201A1 (es) 2000-05-24
HRP970664A2 (en) 1998-10-31
PT946512E (pt) 2004-01-30
DK0946512T3 (da) 2004-01-12
NO313517B1 (no) 2002-10-14
OA11123A (en) 2003-04-07
AU4791797A (en) 1998-06-29
SK70899A3 (en) 2002-04-04
IL130111A0 (en) 2000-06-01
NZ335733A (en) 2001-01-26
AU7205001A (en) 2001-11-15
WO1998024766A1 (fr) 1998-06-11
TR199901259T2 (xx) 1999-08-23
KR100360633B1 (ko) 2002-11-13
CN1239952A (zh) 1999-12-29
MA26453A1 (fr) 2004-12-20
DE69725465D1 (de) 2003-11-13
HUP0001848A3 (en) 2002-03-28
DZ2361A1 (fr) 2002-12-28
KR20000057413A (ko) 2000-09-15
US20020032191A1 (en) 2002-03-14
HN1997000027A (es) 1997-06-05
ZA9710906B (en) 1999-06-09

Similar Documents

Publication Publication Date Title
EP0946512B1 (fr) Derives de 6-phenylpyridyl-2-amine utilises comme inhibiteurs de nos
CA2890981A1 (fr) Composes heterocycliques substitues par amide, utiles comme modulateurs d'il-12, il-23 et/ou de reponses a l'ifn?
JP2007008816A (ja) 新規イソキノリン誘導体
WO1995028387A1 (fr) Compose benzamide et utilisation medicale dudit compose
TW200526620A (en) Pyrazine derivatives and pharmaceutical use thereof
KR101268890B1 (ko) 메타니코틴 화합물의 하이드록시벤조에이트 염
US10112945B2 (en) Fused quinoline compunds as PI3K, mTOR inhibitors
TW201038554A (en) Nicotinamide derivatives, their preparation and their therapeutic application
JP2501298B2 (ja) モルフアナン類のｏ−アリ―ルエ―テル
US10730878B2 (en) Fused quinoline compounds as PI3K/mTOR inhibitors
CN111278814B (zh) 作为毒蕈碱m1受体正向别构调节剂的多环酰胺
CN116601153B (zh) 作为nav1.8抑制剂的含氮2,3-二氢喹唑啉酮化合物
FR2593818A1 (fr) Derives d'acylaminomethyl-3 imidazo(1,2-a)pyridine, leur preparation et leur application en therapeutique
CN113891879B (zh) 3,6-二取代的-2-吡啶醛肟骨架
US20200172536A1 (en) PYRIDO[2,3-d]PYRIMIDIN-7-ONES AND RELATED COMPOUNDS AS INHIBITORS OF PROTEIN KINASES
SK17122002A3 (sk) Derivát heterocyklického aminoalkylpyridínu ako psychofarmaceutické činidlo, spôsob jeho prípravy, jeho použitie a farmaceutický prostriedok, ktorý ho obsahuje
JP3444495B2 (ja) 酸化窒素合成酵素阻害剤として縮合環置換基を含有する２−アミノピリジン
WO2024166024A1 (fr) Nouveau composé et composition pharmaceutique le comprenant
JP2011508758A (ja) Ｎ−フェニルイミダゾ［１，２−α］ピリジン−２−カルボキサミド誘導体、これらの調製およびこれらの治療用途
US20040142924A1 (en) 6-Phenylpyridyl-2-amine derivatives useful as NOS inhibitors
CN111808080B (zh) 取代的吡啶或嘧啶化合物、其制备方法及其在医药上的应用
EP2411367A1 (fr) Derives anticancereux, leur preparation et leur application en therapeutique
JPH1081622A (ja) 新規な一酸化窒素合成酵素阻害剤